首页> 外文期刊>Oncology letters >Effect of CXCL12/CXCR4 on increasing the metastatic potential of non-small cell lung cancer in vitro is inhibited through the downregulation of CXCR4 chemokine receptor expression
【24h】

Effect of CXCL12/CXCR4 on increasing the metastatic potential of non-small cell lung cancer in vitro is inhibited through the downregulation of CXCR4 chemokine receptor expression

机译:通过下调CXCR4趋化因子受体表达,抑制了CXCL12 / CXCR4对非小细胞肺癌体外转移潜能的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Lung cancer ranks as the most common type of cancer in males worldwide. Although great advances have been achieved in chemotherapy and radiotherapy, the long-term survival rate of lung cancer patients has not improved significantly. Dissemination of lung cancer in the thoracic cavity and metastatic spread to the liver, bone and brain are characteristic of non-small cell lung cancer (NSCLC), constituting the primary source of morbidity and mortality in lung cancer. Increasing evidence also indicates that the CXC chemokine receptor 4 (CXCR4)/chemokine CXC motif ligand 12 (CXCL12) chemokine axis is important for the cell invasion and migration of lung cancer. CXCR4 is a G protein-coupled receptor with a major role in lymphocyte homing. Its ligand, CXCL12, is secreted by target organs and functions as a highly efficient chemotactic factor for T cells, monocytes, pre-B cells, dendritic cells and myeloid bone marrow-derived cells. In the current study, recombinant CXCR4-specific small interfering RNA-pBSilence1.1 plasmids were constructed and transfected into the A549 NSCLC cell line in vitro. Reverse transcription polymerase chain reaction and western blotting revealed that CXCR4 was downregulated in transfected cells compared with control cells. The results of MTT and Transwell migration assays indicated that the specific downregulation of CXCR4 inhibited cell growth, invasiveness and migration. Thus, siRNA targeting of CXCR4 may effectively inhibit the effect of CXCL12/CXCR4 on increasing the metastatic potential of NSCLC.
机译:肺癌是全世界男性中最常见的癌症类型。尽管化学疗法和放射疗法已经取得了很大的进步,但是肺癌患者的长期存活率并未显着提高。非小细胞肺癌(NSCLC)的特征是肺癌在胸腔中的扩散以及转移扩散到肝脏,骨骼和大脑的扩散,是肺癌发病率和死亡率的主要来源。越来越多的证据还表明,CXC趋化因子受体4(CXCR4)/趋化因子CXC基序配体12(CXCL12)趋化因子轴对肺癌的细胞侵袭和迁移很重要。 CXCR4是一种G蛋白偶联受体,在淋巴细胞归巢中起主要作用。它的配体CXCL12由靶器官分泌,并作为T细胞,单核细胞,B前细胞,树突状细胞和骨髓骨髓来源的细胞的高效趋化因子。在本研究中,构建了重组CXCR4特异性小干扰RNA-pBSilence1.1质粒,并在体外转染到A549 NSCLC细胞系中。逆转录聚合酶链反应和免疫印迹表明,与对照细胞相比,CXCR4在转染细胞中被下调。 MTT和Transwell迁移分析的结果表明,CXCR4的特异性下调抑制了细胞的生长,侵袭性和迁移。因此,靶向CXCR4的siRNA可以有效抑制CXCL12 / CXCR4对增加NSCLC转移潜能的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号